Commercialization: Page 14
-
Commercial Influencers
Influencers have the power to positively change the status quo because of their authority, knowledge, position, or relationship with their audience. According to the global consultancy Evaluate, the impact of COVID-19 has so far wiped $7.85 billion off forecasts for biopharma sales in 2020, with ...
By PharmaVoice Team • Oct. 1, 2020 -
Roshawn Blunt — Optimizing a Strategic Plan
Given cell and gene therapies are typically personalized medicines, they come with outlier pricing and other unique commercialization challenges that differ from other large and small molecule therapies. Roshawn Blunt, a respected biotech consultant, was inspired by President John Adams, who in 1...
By Roshawn Blunt • Oct. 1, 2020 -
Greg Skalicky — Understanding the Commercial Lifecycle
By building a complete commercial platform, we are able to take a broad view of how market and product complexities impact operations. With a wide breadth of clinical and commercial experience, Greg Skalicky, chief revenue officer of EVERSANA, has a keen understanding of the entire product lifecy...
By Greg Skalicky • Oct. 1, 2020 -
SHOWCASE: Artificial Intelligence: Driving Drug Innovation With AI
The global AI market has been showing rapid growth as major pharmaceutical and medical technology companies invest heavily in internal and external AI partnerships. According to some reports, more than 50% of executives expect broad scale AI adoption by 2025. Further, revenue generated through AI...
By PharmaVoice Team • Oct. 1, 2020 -
Case Study: Leveraging AI for Meaningful Clinical Trials
Clinical trial sponsors seeking to develop new drugs and therapies face unique challenges, particularly when it comes to understanding patient dosing and response to therapy. This aspect can be difficult, as patients often: Do not take their medicine regularly, or at all Take creative measures to...
By Rich Christie • Oct. 1, 2020 -
How AI Can Improve Understanding of Patient's Behavior and Symptoms
Running and managing clinical trials, at the most basic level, is about creating a foundation to get the best possible data. While a great deal of thought goes into recruiting the right patients and developing the most effective protocols, initiatives designed to improve the experience for the pa...
By Michelle Marlborough • Oct. 1, 2020 -
5 Steps to Intelligent Omnichannel Engagement
The future of HCP engagement in the post-pandemic world isn’t clear. But in the wake of pharma’s forced digital migration, the need for an effective omnichannel strategy is. Luckily, most commercial teams already have a strong data and analytics infrastructure in place and are beginning to activa...
By Matthew Van Wingerden • Oct. 1, 2020 -
Technology-Driven Pharmacovigilance Operations
Improving Data Quality and Compliance while Reducing Cost with AI Traditionally, the pharmacovigilance (PV) function has been responsible for collecting, assessing, and reporting safety information to health authorities, sites, and other stakeholders. Companies have invested in safety systems to ...
By Dinesh Kasthuril • Oct. 1, 2020 -
AI and Drug Discovery
Discovering and bringing new drugs to market is notoriously slow and costly for a reason. Science moves slowly because of the incredibly complex nature of human biology and the difficulty of sluggish recruitment of clinical trials. And in spite of greater investments in R&D by pharmaceutical ...
By Claire Bonaci • Oct. 1, 2020 -
The Accessibility of AI: Innovation at Your Fingertips
The availability of datasets keeps growing exponentially. With this we are witnessing an escalation of available new life-altering systems. Some of these tools are highly autonomous and can perform functions with little to no human intervention. Self-driving cars, rockets that land upright on dro...
By Max Divak • Oct. 1, 2020 -
AI-Driven Marketing
We have all seen those digital banners that are somehow related to what we’re looking at online and appear to follow us wherever we are. Don’t worry, there is nothing ominous at play and the government is not listening to our conversations through our devices. But this is not completely coinciden...
By J.P. Maranzani • Oct. 1, 2020 -
Leveraging AI to Slingshot Drugs from Lab to Market
The science of clinical development continually astounds even those of us intimately connected to it. We recognize that our overarching industry mandate — to develop and deliver safe and effective new therapies to fight and cure disease — must be continually informed by new thinking and tools if ...
By Malai Sankarasubbu • Oct. 1, 2020 -
The Salesforce of the Future
COVID-19 is fast-tracking the industry’s slow move from fewer in-person HCP visits to digital and virtual approaches. COVID-19 has driven vast changes in what healthcare providers need and value from pharma companies, and as a result, the industry is striving to develop new ways to engage with ph...
By Robin Robinson • Oct. 1, 2020 -
SHOWCASE: Patient Solutions: The Changing Face of Patient Engagement
Digital technologies are changing the healthcare landscape, creating opportunities for patient-support programs, patient monitoring and self-management. There is massive demand for patient-engagement solutions, with predictions that the market for such solutions will reach $30.36 billion by 2026....
By PharmaVoice Team • Oct. 1, 2020 -
Advancing Beyond the Traditional Patient Adherence Model
Delivering value in the era of empowered patients renders the one-size-fits-all patient services program obsolete. Not every treatment journey is consistently linear within a disease state because patients take different paths to medication adherence. For example, one patient may be compliant whe...
By Maria Kirsch • Oct. 1, 2020 -
Social Connection Is Possible in a Time of Physical Distancing
In this time of physical distancing, technology often seems like the go-to solution for helping people connect. However, data linking social media and depression, as well as research pointing to social divisiveness online, might give us pause. Recent survey results found most Americans believe th...
By Amrita Bhowmick • Oct. 1, 2020 -
Listening to the Patient for Better Outcomes
The aim of drug development is to improve patient outcomes. Historically, clinical research has been driven by researchers, with little or no input from patients, contributing to many of the challenges and inefficiencies we see in today’s clinical trials. Some of these challenges include low enro...
By Gretchen Goller • Oct. 1, 2020 -
Speak Out: The Power of Virtual Patient Simulation in CME
Simulation as we think of it today has been used in medical education since the 18th century,1 and has continued to evolve into realistic and medically accurate physical and digital solutions designed to allow learners to simulate a scenario-based encounter with a patient in a safe environment. V...
By Martin Warters • Oct. 1, 2020 -
Executive Perspective: AI With a Healthcare IQ: A Conversation with Lucas Glass and Andrew Ploszay
Since the term was first coined in 1955, “artificial intelligence" (AI) has led to significant advances across industries. From robotics to automobiles, to digital personal assistants, and even online shopping. In healthcare, AI has enabled many successes, but a few noteworthy failures have made ...
By Lucas Glass • Oct. 1, 2020 -
Letter from the Editor
What’s Next … Over the past several months, I, like everyone else, have wondered what’s next? What’s next if there’s not a vaccine approved soon? And, even if a vaccine is approved, how does that play out? What happens if there’s a next wave of COVID-19 that coincides with flu season? The what if...
By Taren Grom • Sept. 1, 2020 -
Upfront
Bristol Myers Squibb Commits $300 Million to Health Equity and Diversity and Inclusion Efforts Bristol Myers Squibb and the BMS Foundation are investing $300 million over the next five years to accelerate and sustain its diversity, equity, and inclusion efforts. Specifically, the company will foc...
By PharmaVoice Team • Sept. 1, 2020 -
HealthTech
Amwell Telehealth Use Swells During Pandemic Trend Watch: Technology Rises to the Challenges of COIVD-19 Amwell, a national telehealth company, which has been gaining app usage since the onslaught of COVID-19, has hired a new Chief Technology Officer Serkan Kutan. Mr. Kutan who comes from executi...
By PharmaVoice Team • Sept. 1, 2020 -
Artificial Intelligence
SOPHiA Genetics’ First Multimodal Approach to Predict COVID-19 Disease Evolution Trend Watch: AI Technology Helps in the Fight Against COVID-19 Health-tech company SOPHiA Genetics, specializing in data-driven medicine, has launched a first-of-its-kind multimodal solution to predict COVID-19 disea...
By PharmaVoice Team • Sept. 1, 2020 -
Last Word
Changing the Patient–Scientist Dialogue Paul Kidwell, Senior Public Relations/Patient Advocacy Consultant & Podcaster, for the life-sciences industry provides an insider’s view into the need for increased communication between patients and scientists. PV: What has been your experience in term...
By Paul Kidwell • Sept. 1, 2020 -
SHOWCASE: Big Data: Big is Better: The Importance of Data in Industry Advances
Big data is big business, and for the life-sciences and healthcare industries it’s playing an important role in informing everything from R&D to commercialization. With the growth of digital healthcare, it is estimated that the amount of data the industry is collecting is increasing by around...
By PharmaVoice Team • Sept. 1, 2020